Compare Nasdaq100 ETF (QQQ) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nasdaq100 ETF vs Regeneron Pharmaceuticals Inc — how do they compare? Nasdaq100 ETF trades at $753.73 (market cap $506.92B), while Regeneron Pharmaceuticals Inc trades at $740 (market cap $76.14B). The key difference: Nasdaq100 ETF is far larger — about 6.7× Regeneron Pharmaceuticals Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while Nasdaq100 ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nasdaq100 ETF for 162 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| QQQ | REGN | |
|---|---|---|
Market Cap | $506.92B | $76.14B |
Volume | 48,326,518 | 500,239 |
52-Week High | $759.66 | $852.03 |
52-Week Low | $558.34 | $557.73 |
Typical Hold Time | 162 Days | 107 Days |
Sector | — | Health |
Enterprise Value | — | $70.85B |
Dividend Yield | — | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QQQ trades at $757.73, down 0.25% on the day, with a bullish technical signal from moving averages but bearish oscillators. The ETF shows mixed analyst sentiment with a 50% buy and 50% sell consensus. Recent news highlights comparisons with lower-fee alternatives like QQQM and VOO, while broader market concerns about AI valuations and interest rate impacts create headwinds.
The outlook for QQQ remains tied to technology sector performance and AI-driven growth, though elevated valuations and concentration risk warrant caution. Near-term support lies at $754, with resistance at $760. Investors face balancing growth potential against fee differentials and market volatility risks.
Regeneron Pharmaceuticals (REGN) trades at $742.12, up 0.46% on the day, with a bearish technical signal despite strong fundamentals. The stock shows robust profitability with a 27.86% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront and milestone payments.
The outlook is positive due to strong earnings momentum and strategic collaborations, but risks include competitive pressures in key drug markets and technical bearish indicators. Analyst consensus is bullish with a $849.84 price target, suggesting potential upside from current levels, though investors should monitor execution of new partnerships and pipeline developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Nasdaq100 ETF
The ETF is designed to track the performance of the securities and the stocks in the NASDAQ-100 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on QQQ →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
